Summary
This 2024 observational study quantifies the intersection of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease (MASLD), characterising diabetes prevalence within MASLD cohorts and its associations with cardiometabolic outcomes. The work addresses an important epidemiological gap in understanding dual hepatic and metabolic dysfunction as a risk phenotype. Specific cardiometabolic effect estimates and clinical endpoints require confirmation from the full text.
Regional applicability
The study was conducted in a patient population with MASLD and type 2 diabetes; transferability to United Kingdom primary care and hepatology practice depends on patient demographics and healthcare system context, which are not specified in the available metadata. MASLD and type 2 diabetes comorbidity is increasingly prevalent in UK populations, making the risk stratification findings potentially applicable if the cohort characteristics align with UK patient populations.
Key measures
Diabetes prevalence in MASLD populations; cardiometabolic outcomes and risk factors (specific endpoints require full-text confirmation)
Outcomes reported
The study examined the prevalence of type 2 diabetes mellitus in populations with metabolic dysfunction-associated steatotic liver disease (MASLD) and quantified associations between diabetes status and cardiometabolic outcomes in this comorbid population.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.